RLFTF stock
Biotech

Why RLFTF Stock Is The Best COVID-19 Bet

Right now a lot of traders and investors are asking what the next move to make in regards to COVID-19 plays. Many of the high-flyers have seen some bursting of the bubble on the myriad of vaccine news that has hit the tape recently. This has caused many of the COVID-19 vaccine runners like Sorrento Therapeutics, Inovio Pharmaceuticals, and Moderna to all drop 57%, 62%, and 30% from their respective highs. Luckily, our readers and subscribers have been in Moderna since $21, Inovio since $5, and Sorrento since $4.

The recent weakness is to be expected once it was reported that a Hong Kong man contracted the coronavirus twice in the same year. Most experts were under the impression that once someone had COVID-19, that they would be immune from catching it again. This new development has investors reassessing the best play – vaccine or treatment. In our opinion, the best play now is in treatment and the one company with the most potential is RLFTF stock. In this article, we will explain why.

RLFTF Stock

First up, here’s a little background info for those not familiar with RLFTF stock. RELIEF THERAPEUTICS Holding AG focuses primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.

Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis.  Relief Therapeutics also holds a U.S. patent (US8178489 formulation for aviptadil) for RLF-100 and proprietary manufacturing processes for its synthesis.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and in the US on the OTC Markets under the symbol RLFTF.

How COVID-19 Attacks The Body

The SARS-CoV-2 virus directly targets and incapacitates certain lung cells. This can create a domino effect of severe trauma to the lungs, and trigger an out of control immune system response which can further exacerbate the trauma. Here are the 5 steps:

  1. COVID-19 attacks type 2 alveolar cells (AT-II) in the lungs.
  2. These AT-II cells are key to getting oxygen into the bloodstream.
  3. The destruction of these AT-II lung cells by COVID-19 decreases lung function because oxygen is no longer being transferred into the blood
  4. COVID-19’s occupancy of the ACE2 receptor of the AT-II cells increases vasoconstriction and blood pressure, and cytokine release.
  5. The Cytokine Release Syndrome (CRS), also known as the Cytokine Storm, which is the body’s out-of-control immune system activation causes the lungs to fill with fluid (pulmonary edema).

RLF-100

RLF-100™, also known as Aviptadil, is a synthetic form of Vasoactive Intestinal Polypeptide (VIP). RLF-100™ has been granted Fast Track Designation and is currently in phase 2/3 placebo-controlled trials (NCT04311697).

FDA has granted Emergency Use IND and Expanded Access Protocol approval for the use of RLF-100™ in patients whose comorbidities render them ineligible for inclusion in the ongoing pivotal trial.

In the latest announcement from BARDA, 19 of 21 patients have survived. The improved radiographic appearance was seen in both lungs of 17 patients and in one lung of 2 patients. A mean 292% increase in PaO2: FiO2 ratio was seen with complete remission from respiratory failure in 9 patients and ongoing improvement in 10. Seven patients were discharged from the hospital, 7 sent to intermediate care, and 5 remain in the ICU. Three of 5 patients on ECMO have been decannulated and two have been discharged. A 75% (95% CI±3%: P<.001) reduction in IL-6 was seen with a corresponding decrease in C-reactive protein. A median 4 point reduction in the NIAID Ordinal Scale was observed (P<.01).

The short term outcomes in these 21 patients represent a dramatic response in patients who are excluded from all other trials of COVID therapeutics. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of a direct anti-viral effect.

The findings of Dr. Youssef and his team demonstrate that some critically ill patients with COVID-19 experienced a substantial clinical improvement when treated with RLF-100. We await the results of the ongoing placebo-controlled trial in order to assess the magnitude of clinical effect.

Why All The Excitement?

In the following chest X-ray, you can see the improvements in the lungs. After 14 days, the patient was discharged from the hospital and breathing normally.

This is a major development in the treatment of COVID-19. For more understanding, we recommend watching this video Dr. Yo conducted with Dr. Jonathan Javitt who is leading the study.

As Dr. Javitt says, no other treatment has shown the rate of improvement as RLF-100, not Remedisivir, and not Leronlimab. This is huge news and why RLFTF stock is a bargain at a $1 billion market cap. CytoDyn has a current market cap of $2.1 billion and Gilead $82 billion. How much is an effective treatment for COVID-19 worth? It’s safe to say, much more than $1 billion. All indications are that RLF-100 is effective and we are waiting for the next results to hit the tape. Currently, firefighter Thomas Searcy is being treated with RLF-100, and his wife posts updates on Facebook. This is a good way to monitor his progress and the efficacy of RLF-100.

Unlike expensive-to-produce monoclonal antibodies and difficult-to-scale convalescent plasma, VIP can ultimately be produced at a cost of pennies per dose, if moved from peptide synthesis to yeast fermentation, as is done for insulin. As such, it may represent a critical therapeutic for COVID-19 and possibly other viral infections for both the developed and the developing world. No doubt the White House has taken notice and with the upcoming election and Trump needing a win, we could see emergency fast-track approval under Operation Warp Speed along with federal funding for RLF-100. For all these reasons, we believe RLFTF stock is the best COVID-19 bet right now.

As always, good luck to all (except the shorts)!

We will be updating our subscribers as soon as we know more. For the latest updates on OTCMKTS:RLFTF, sign up today!

Disclosure: We have no position in OTCMKTS:RLFTF or any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.

Image by oracast from Pixabay

GET NOTIFIED
Sign up for our next MicroCap Runner ahead of the crowd!
We hate spam. No Hidden Fees. Unsubscribe Anytime.
Why RLFTF Stock Is The Best COVID-19 Bet
Click to comment
To Top